Filter
227
Featured
19
11
Language
Document type
200
8
7
4
3
2
2
1
Countries / Regions
23
18
14
12
11
9
5
4
3
3
3
2
2
2
2
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
15
14
8
4
1
1
Q7: For people with dementia, who should be told of the diagnosis and how should the diagnosis be delivered?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
The report “Dementia: a public health priority” has been jointly developed by WHO and Alzheimer's Disease International. The purpose of this report is to raise awareness of dementia as a public health priority, to articulate a public health approach and to advocate for action at international a
...
Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?
Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?
Q6: What is the added advantage of doing neuroimaging in people with convulsive epilepsy in non-specialist settings in low and middle income countries?
Q3: Can febrile seizures (simple or complex) be managed at first or second level care by non-specialist health care providers in low and middle income country settings? What is the role of diagnostic tests in the management of febrile seizures by non-specialists in low and middle income settings? Fo
...
Q5: What is the added advantage of doing an electroencephalography (EEG) in people with convulsive epilepsy in non- specialist settings in low and middle income countries?
Q8. Should Anti-Epileptic Drug (AED) treatment be started after first unprovoked seizure in non-specialist health settings?
Q 7: For adults and children with convulsive epilepsy, which standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) when compared to placebo/a comparator produce benefits/harm in the specified outcomes?
Q4: Can convulsive epilepsy be diagnosed at first level care by a non-specialist health care provider in low and middle income country settings?
Q12: Should the treatment be similar in individuals with intellectual disability and epilepsy compared to people with epilepsy only?
Q11: 11a). In women with epilepsy, should antiepileptic therapy be prescribed as monotherapy or polytherapy to decrease the risk of fetal malformations?
11b). Does the use of folic acid preconceptually decrease the risk of foetal malformations in women with epilepsy?
11c). Do phenytoin, phenobarbi
...
Bulletin de l'Organisation mondiale de la Santé 2012;90:871-871A. doi: 10.2471/BLT.12.113183
Bulletin de l'Organisation mondiale de la Santé Numéros précédents Volume 90: 2012 Volume 90, Numéro 12, décembre 2012, 869-944
В методических рекомендациях представлены современные подходы к терапии поведенческих и психотических расстройств у пациентов с болезнью Альцгеймера. Ведение т
...
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
Цель: анализ уровня тревожности и тяжести депрессии у больных рассеянным склерозом. Материал и методы. Чтобы определить уровень депрессии и тревожности у больных
...
Q1: What are the effective maternal mental health interventions to prevent developmental problems in early infancy?
Paediatrics
Chapter I.2
La demencia es una enfermedad gravemente incapacitante para aquellos que la padecen y suele ser devastadora para sus cuidadores y familiares. Se estima que en la actualidad 35.6 millones de personas viven con demencia a nivel mundial. Este número se habrá casi duplicado para el 2030 y más que tri
...
